학술논문
Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry.
Document Type
Academic Journal
Author
Alawawdeh A; Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia.; Piantadosi C; Division of Surgery, Flinders Medical Centre, Adelaide, SA, Australia.; Townsend AR; Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia.; Karapetis CS; Department of Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.; Padbury R; Division of Surgery, Flinders Medical Centre, Adelaide, SA, Australia.; Roy AC; Department of Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.; Moore J; Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.; Maddern G; Department of Surgery, The Queen Elizabeth Hospital, Adelaide, SA, Australia.; Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia.; Roder D; Sansom Institute for Health Research, Adelaide, SA, Australia.; Smith A; Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia.; Price TJ; Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, Adelaide, SA, Australia. Timothy.Price@sa.gov.au.; TQEH, 28 Woodville Road, Woodville, SA, 5011, Australia. Timothy.Price@sa.gov.au.
Source
Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Effective targeting of RAS mutations has proven elusive until recently. Novel agents directly targeting KRAS G12C have shown promise in early-phase clinical trials that included patients with metastatic colorectal cancer. Prior reports have suggested that G12C mutation may be predictive of poor outcome.
Objective: Assessment of the specific characteristics and prognostic implications of individual RAS mutation subtypes in patients with metastatic colorectal cancer.
Patients and Methods: Retrospective review of individual RAS mutation types from the South Australian Metastatic Colorectal Registry between 2006 and 2020.
Results: Of the 5165 patients entered onto the registry, 2305 (45%) had RAS mutation results available. 772 (33%) had a RAS mutation. The nature of the RAS mutation was available in 668 (87% of those with RAS mutation). Rare mutations (outside codons 12 and 13) made up 12.6% of the total. There were numerical differences in survival between the specific RAS mutation subgroups, with the longest median overall survival (30 months) observed in those with G12S mutations. However, there was no statistical difference in survival when comparing the various RAS mutations, including the comparison of G12C to G12S (p = 0.38). Patients with cancer harbouring rare RAS mutations had a median survival of 30 months.
Conclusions: Whilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ.
(© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Objective: Assessment of the specific characteristics and prognostic implications of individual RAS mutation subtypes in patients with metastatic colorectal cancer.
Patients and Methods: Retrospective review of individual RAS mutation types from the South Australian Metastatic Colorectal Registry between 2006 and 2020.
Results: Of the 5165 patients entered onto the registry, 2305 (45%) had RAS mutation results available. 772 (33%) had a RAS mutation. The nature of the RAS mutation was available in 668 (87% of those with RAS mutation). Rare mutations (outside codons 12 and 13) made up 12.6% of the total. There were numerical differences in survival between the specific RAS mutation subgroups, with the longest median overall survival (30 months) observed in those with G12S mutations. However, there was no statistical difference in survival when comparing the various RAS mutations, including the comparison of G12C to G12S (p = 0.38). Patients with cancer harbouring rare RAS mutations had a median survival of 30 months.
Conclusions: Whilst the G12S mutation was associated with the longest survival numerically, the observed survival for patients with the most common RAS mutations (G12C, G12V, G12A, G12D and G13D) did not significantly differ.
(© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)